Zevra Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance
Zevra Therapeutics, Inc. (ZVRA) had Deferred Tax Assets, Valuation Allowance of $91.50 million as of 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-09
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $91.50M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $146.36M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $134.49M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $81.83M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $91.50M 10-K · filed 2026-03-09 |
| 2024-12-31 | $146.36M 10-K · filed 2026-03-09 |
| 2023-12-31 | $134.49M 10-K · filed 2025-03-12 |
| 2022-12-31 | $81.83M 10-K · filed 2024-04-01 |
| 2021-12-31 | $72.51M 10-K · filed 2023-03-07 |
| 2020-12-31 | $70.09M 10-K · filed 2022-03-31 |
| 2019-12-31 | $67.19M 10-K · filed 2021-03-12 |
| 2018-12-31 | $60.19M 10-K · filed 2020-02-28 |
| 2017-12-31 | $42.97M 10-K · filed 2019-03-01 |
| 2016-12-31 | $48.78M 10-K · filed 2018-03-30 |
| 2015-12-31 | $29.02M 10-K · filed 2018-03-30 |
| 2014-12-31 | $18.10M 10-K · filed 2017-03-10 |
| 2013-12-31 | $10.40M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |